Veloxity Labs Acquires SCIEX Accurate Mass Spectrometer, the ZenoTOF 8600 System, To Accelerate Peptide and Complex Bioanalysis

Veloxity Labs, announced the acquisition of the ZenoTOF 8600 system from SCIEX. Veloxity is the first bioanalytical CRO in the United States to acquire this new accurate mass spectrometer, with delivery expected later this year and installation/qualification starting January of 2026. With this acquisition, Veloxity is expanding its toolkit for peptide and protein bioanalysis—strengthening method development speed, identity confirmation and interference resolution—while complementing its existing LC–MS/MS (triple quadrupole) platforms.  

The ZenoTOF 8600 system investment is a key part of Veloxity’s continued lab expansion, with expectations of adding an additional instrument lab, increased freezer storage and room for team growth later this year. This facility growth signals long-term stability and near-term capacity for sponsors planning GLP-enabling and Phase 1/2 work.  

“Adding the ZenoTOF 8600 system gives our scientists a faster, more selective way to solve hard problems, especially in peptide and complex matrix workflows,” noted Shane Needham, PhD, CoFounder, President & CEO, Veloxity Labs. “We’re investing in innovation that will create an immediate impact on sponsor timelines: quicker method cycles, better tools to handle interferences and added sensitivity headroom for GLP-1 receptor agonists and other peptides. It’s a natural fit with our model of speed with purpose and our growth in capacity.” 

What the ZenoTOF 8600 system brings to sponsors: 

• Peptide momentum (incl. GLP-1 RAs): HRAM selectivity/sensitivity and expanded mass range for intact peptides and proteins accelerate method setup and refinement, with headroom for low levels and small volumes.
• Confidence in complex matrices: Enhanced selectivity supports interference deconvolution and confirmation when biological matrices challenge traditional assays.  
• Built to complement triple-quads: Routine regulated quantitative analysis stays efficient on triple-quads; the ZenoTOF 8600 system adds a problem-solving and selectivity path that can shorten overall development cycles for complex modalities.  
• Continuity across phases: Methods and records are designed to carry forward efficiently, supporting an efficient transition from discovery to GLP and clinical with ICH M10-aligned practices. 

“We’re excited to support Veloxity’s early adoption of the ZenoTOF 8600 system. HRAM technology helps labs confirm identity, resolve challenging interferences and advance sensitive workflows—capabilities that matter for today’s peptide-rich pipelines,” said Jose Castro-Perez, Vice President, Product Management at SCIEX. “Veloxity’s focus on efficiency and scientific rigor makes them an ideal partner to showcase what the ZenoTOF 8600 system can unlock.”